Impact of angiotensin blockade on response to PD1/L1 inhibitors for patients with metastatic urothelial carcinoma (mUC).

被引：0
|
作者：
Skelton, William Paul [1 ]
Jain, Rohit K. [2 ]
Curran, Catherine [3 ]
Pond, Gregory Russell [4 ]
Naqvi, Syeda Mahrukh Hussnain [5 ]
Kim, Youngchul [1 ]
Nuzzo, Pier Vitale [3 ]
Abou Alaiwi, Sarah [3 ]
Nassar, Amin [6 ]
Jain, Rakesh K. [7 ]
Sonpavde, Guru [8 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Lee Moffitt Canc Ctr, Tampa, FL USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] McMaster Univ, Dept Oncol, Hamilton, ON, Canada
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[6] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[7] Massachusetts Gen Hosp, Boston, MA 02114 USA
[8] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.453
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
453
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
    Serrati, Simona
    Guida, Michele
    Di Fonte, Roberta
    De Summa, Simona
    Strippoli, Sabino
    Iacobazzi, Rosa Maria
    Quarta, Alessandra
    De Risi, Ivana
    Guida, Gabriella
    Paradiso, Angelo
    Porcelli, Letizia
    Azzariti, Amalia
    MOLECULAR CANCER, 2022, 21 (01)
  • [42] Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR2/3 genetic alterations (GAs).
    Jain, Rohit K.
    Kim, Youngchul
    Rembisz, Jennifer
    Piekarz, Richard
    Synold, Timothy W.
    Zhang, Jingsong
    Sonpavde, Guru P.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [43] Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR2/3 genetic alterations (GAs).
    Jain, Rohit K.
    Heiligh, Jazlyn
    Kim, Youngchul
    Piekarz, Richard
    Pelosof, Lorraine Cheryl
    Yang, Yuanquan
    D'souza, Anishka
    Wong, Risa Liang
    Graham, Laura
    Gupta, Sumati
    Park, Anna
    Synold, Timothy W.
    Sonpavde, Guru P.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 625 - 625
  • [44] Real-world outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) who received first- (1L) or second-line (2L) PD-1 and PD-L1 inhibitors in the United States (US)
    Boyd, M.
    Annavarapu, S.
    Doshi, G. K.
    Imai, K.
    Sbar, E. I.
    Godwin, J. L.
    Li, H.
    Sonpavde, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S599 - S599
  • [45] Checkpoint inhibitors anti PD1/PDL1 in metastatic NSCLC
    Hirsh, Vera
    JOURNAL OF TRANSLATIONAL MEDICINE, 2017, 15
  • [46] Real-world effectiveness of single agent enfortumab vedotin (EV) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) based on line of therapy and impact of prior platinum (plat) chemotherapy (chemo) and PD-1/PD-L1 inhibitors (PD-1/PD-L1i)
    Sayegh, N.
    Jo, Y. Jung
    Gebrael, G.
    Tripathi, N.
    Chigarira, B.
    Srivastava, A.
    Nordblad, B.
    Dal, E.
    Chehade, C. Hage
    Maughan, B. L.
    Gupta, S.
    Agarwal, N.
    Swami, U.
    ANNALS OF ONCOLOGY, 2023, 34 : S1212 - S1212
  • [47] IK-175, an oral AHR inhibitor, as monotherapy and in combination with nivolumab in patients with urothelial carcinoma resistant/refractory to PD-1/L1 inhibitors
    Aggen, David H.
    McKean, Meredith
    Hoffman-Censits, Jean H.
    Lakhani, Nehal J.
    Alhalabi, Omar
    Guancial, Elizabeth A.
    Bashir, Babar
    Bowman, I. Alex
    Tan, Alan
    Lingaraj, Trupti
    Kim, Katherine
    Timothy, Marissa
    Ortiz-Otero, Nerymar
    Bartolini, Wilmin
    Kacena, Katherine
    Santillana, Sergio
    Luke, Jason J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Novel treatments using PD1 inhibitors for advanced and metastatic cutaneous squamous cell carcinoma
    Pezeshki, Saharnaz
    Hemmati, Sara
    Rezaei, Nima
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (10) : 819 - 822
  • [49] Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
    David Liu
    Bastian Schilling
    Derek Liu
    Antje Sucker
    Elisabeth Livingstone
    Livnat Jerby-Arnon
    Lisa Zimmer
    Ralf Gutzmer
    Imke Satzger
    Carmen Loquai
    Stephan Grabbe
    Natalie Vokes
    Claire A. Margolis
    Jake Conway
    Meng Xiao He
    Haitham Elmarakeby
    Felix Dietlein
    Diana Miao
    Adam Tracy
    Helen Gogas
    Simone M. Goldinger
    Jochen Utikal
    Christian U. Blank
    Ricarda Rauschenberg
    Dagmar von Bubnoff
    Angela Krackhardt
    Benjamin Weide
    Sebastian Haferkamp
    Felix Kiecker
    Ben Izar
    Levi Garraway
    Aviv Regev
    Keith Flaherty
    Annette Paschen
    Eliezer M. Van Allen
    Dirk Schadendorf
    Nature Medicine, 2019, 25 : 1916 - 1927
  • [50] Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
    Liu, David
    Schilling, Bastian
    Liu, Derek
    Sucker, Antje
    Livingstone, Elisabeth
    Jerby-Amon, Livnat
    Zimmer, Lisa
    Gutzmer, Ralf
    Satzger, Imke
    Loquai, Carmen
    Grabbe, Stephan
    Vokes, Natalie
    Margolis, Claire A.
    Conway, Jake
    He, Meng Xiao
    Elmarakeby, Haitham
    Dietlein, Felix
    Miao, Diana
    Tracy, Adam
    Gogas, Helen
    Goldinger, Simone M.
    Utikal, Jochen
    Blank, Christian U.
    Rauschenberg, Ricarda
    von Bubnoff, Dagmar
    Krackhardt, Angela
    Weide, Benjamin
    Haferkamp, Sebastian
    Kiecker, Felix
    Izar, Ben
    Garraway, Levi
    Regev, Aviv
    Flaherty, Keith
    Paschen, Annette
    Van Allen, Eliezer M.
    Schadendorf, Dirk
    NATURE MEDICINE, 2019, 25 (12) : 1916 - +
12345